Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.

Eva Crespo-RodriguezKatharina BergerhoffGalabina BozhanovaShane FooEmmanuel C PatinHarriet WhittockRichard BuusSyed HaiderGareth MuirheadKhin ThwayKate NewboldRobert S CoffinRichard G VileDae KimMartin McLaughlinAlan A MelcherKevin J HarringtonMalin Pedersen

Published in: Journal for immunotherapy of cancer (2021)

The combination of oHSV and BRAF inhibition significantly improved survival in a mouse model of ATC by enhancing immune-mediated antitumor effects, and triple combination therapies, including either PD-1 or CTLA-4 blockade, further improved therapy.

Keyphrases

wild type
herpes simplex virus
mouse model
metastatic colorectal cancer
stem cells
mesenchymal stem cells